ALLO
Allogene Therapeutics Inc
1.50$
+0.0%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -9.8% | -8.8% | +10.3% | -8.9% | -6.9% | -7.4% | -7.4% | -6.5% | -5.4% | -4.8% | +38.9% | |
| – | -3.0% | -13.9% | +15.6% | -33.4% | -0.3% | -3.9% | -3.1% | -7.8% | -1.1% | +6.0% | +24.4% | |
| – | +20.1% | -38.6% | +234.4% | -70.0% | +46.8% | -43.6% | +23.3% | -27.7% | +36.7% | -41.4% | +27.4% | |
| – | -3.6% | -14.2% | +15.5% | -34.4% | +0.3% | -4.3% | -2.5% | -7.7% | -0.8% | +6.7% | +24.6% | |
| – | +6.3% | +0.0% | +17.6% | +40.0% | -32.1% | +21.1% | -26.1% | +23.5% | -28.6% | -13.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.1% | -4.3% | +5.5% | -4.9% | +0.9% | -3.1% | +2.8% | -1.3% | -0.9% | -5.1% | -2.7% | |
| – | -1.5% | -16.7% | +20.8% | -12.7% | +9.1% | -15.5% | +5.5% | +0.5% | +2.1% | -12.9% | +12.0% | |
| – | +3.0% | +2.3% | +4.2% | +2.3% | +1.6% | +1.6% | +1.6% | +3.2% | +2.5% | +2.6% | – | |
| – | -5.0% | -2.0% | +123.8% | -57.4% | -2.0% | -6.2% | -4.1% | -23.7% | +15.4% | +15.5% | +20.9% | |
| – | -12.2% | -9.9% | +11.6% | -10.0% | -9.0% | -8.7% | -10.6% | -8.5% | -7.2% | -4.7% | +56.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.4% | +0.5% | +12.4% | +10.1% | +0.7% | +2.3% | +1.7% | +1.4% | -0.6% | +8.9% | +36.9% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.